Bavituximab

• CAT Number: I042428
• CAS Number: 648904-28-3
• Molecular Weight: 145.3 (kDa)
• Purity: ≥95%

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1].
Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1)[1].
Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction[1].
Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells[2].
Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo[2].

Reference

[1]. Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6.
 [Content Brief]

[2]. Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591.
 [Content Brief]